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Abstract:   126 
Background: Urothelial carcinoma (UC) is the predominant (95%) bladder cancer 127 
subtype in industrialised nations. Animal and epidemiological human studies suggest 128 
that hormonal factors may influence UC risk. 129 
Methods: We used an analytic cohort of 333 919 women from the European 130 
Prospective Investigation into Cancer and Nutrition Cohort (EPIC). Associations 131 
between hormonal factors and incident UC (overall and by tumour grade, tumour 132 
aggressiveness, and non-muscle invasive UC) risk were evaluated using Cox 133 
proportional hazards models.  134 
Results: During a mean of 15 years of follow-up, 529 women developed UC. In a 135 
model including number of full-term pregnancies (FTP), menopausal status, and 136 
menopausal hormone therapy (MHT), number of FTP was inversely associated with UC 137 
risk (HR≥5vs1=0.48, 0.25-0.90; P-trend in parous women=0.010) and MHT-use 138 
(compared to non-use) was positively associated with UC risk (HR=1.27, 1.03-1.57), 139 
but no dose-response by years of MHT-use was observed. No modification of HRs by 140 
smoking status was observed. Finally, sensitivity analyses in never-smokers showed 141 
similar HR patterns for the number of FTP, while no association between MHT-use and 142 
UC risk was observed. Association between MHT-use and UC risk only remained 143 
significant in current-smokers. No heterogeneity of the risk estimations in the final 144 
model was observed by tumour aggressiveness or by tumour grade. A positive 145 
association between the MTH-use and non-muscle invas ve UC risk was observed. 146 
Conclusion: Our results support that increasing the number of FTP may reduce UC 147 
risk.  148 
Impact: More detailed studies on parity are needed to understand the possible effects of 149 




Key words: Bladder cancer; menopausal hormone therapy; menstrual and reproductive 151 
factors; parity; urothelial carcinoma. 152 
Introduction:   153 
Bladder cancer is the 12th most common cancer in the world, accounting for 4.8% and 154 
1.5% of incident cancers in men and women, respectively(1). In 2018, the estimated 155 
male:female sex ratio in Europe was 4.7 to 1(1). Although, men are at higher risk than 156 
women of developing bladder cancer; women present more advanced stages at 157 
diagnosis(2). In Europe, the 5-year relative survival rate is 84% in men and 75% in 158 
women(3). The predominant bladder cancer subtype is urothelial carcinoma (UC), 159 
accounting for 95% of all cases in industrialised nations(4) and almost 71% of men and 160 
63% of women are diagnosed non-muscle invasive UC(2).  161 
Between 50-64% of UC cases in men and 20-50% in women are attributable to tobacco 162 
use; and the risk increases with both intensity andduration of smoking(5). Other 163 
established risk factors for UC include occupational exposure to aromatic amines and 164 
dyes, ingestion of inorganic arsenic via drinking water, a positive family history, and 165 
constitutional variants in at least a dozen genes(4,6).  166 
Sex differences in UC incidence may be explained to a large extent by sex differences 167 
in the prevalence and intensity of exposure to known risk factors(4). However, after 168 
adjusting for these factors differential risk of bladder cancer persists(2). Thus, several 169 
studies support that female hormones may have a beneficial effect on UC risk. An 170 
experimental animal study that examined the effect of the hormones on oncogenesis in 171 
male rat bladders showed that induced incidence of bladder cancer was higher in the 172 




oestrogen supplementation(7). Moreover, castration of male mice and pregnancy and/or 174 
lactation in female mice can decrease the growth of bladder cancer(8). Previous 175 
epidemiological studies have reported a reduced risk of UC in parous women compared 176 
to nulliparous women(9–12); and an increased risk in postmenopausal women, 177 
particularly those with an earlier age at menopause(11,13,14). In general, no 178 
associations between age at menarche, use of oral contra eptives (OC), age at first full-179 
term pregnancy, breastfeeding and UC risk were observed(9–19). A meta-analysis by 180 
menopausal hormone therapy (MHT) formulation(11), based on four studies, showed a 181 
possible reduction in risk of UC in women who used oestrogen plus progestin MHT 182 
compared to never users of MHT. Nevertheless, in the Women's Health Initiative 183 
(WHI), which included a clinical trial of MHT component and an observational study of 184 
MHT component, no such association was observed(18). To our knowledge, previous 185 
studies examining the association of reproductive factors with UC risk did not stratified 186 
by tumour characteristics (based on tumour grade an tumour stage). 187 
We used a large number of cases (most of them with de ailed UC’s characteristics) 188 
within a large multi-centric prospective study of European women with a long follow-189 
up (15-years) to assess the associations between menstrual factors, reproductive history, 190 
use of exogenous hormones, and the risk of developing UC, overall and by tumour 191 
grade, tumour aggressiveness, and non-muscle invasive UC, and accounting for 192 
smoking status.  193 
Methods: 194 
Study design and population 195 
The European Prospective Investigation into Cancer and Nutrition Cohort (EPIC) is an 196 




ten European countries. The EPIC study was performed in accordance with the 198 
Declaration of Helsinki. All participants signed aninformed consent form, and each 199 
centre obtained approval from the local Ethics Committee. At recruitment (baseline), 200 
information on diet, lifestyle, and anthropometric measurements was collected. Lifestyle 201 
questionnaires included questions on education, occupation, medical history, lifetime 202 
history of consumption of tobacco, alcoholic beverag s, and physical activity. 203 
Questionnaires specific to women were used to collet information on menstrual 204 
factors, reproductive history, and use of exogenous hormones. Details on the study 205 
design have been described previously(20). A total f 521 324 participants were 206 
recruited between 1992 and 2000.  207 
Participants with prevalent cancers, except non-melanoma skin cancer, or participants 208 
with missing follow-up information were excluded (n=29 332). Only women were 209 
eligible for the present analysis (n=343 985). Women with incomplete information on 210 
dietary intake or lifestyle or who had extreme or implausible caloric intake (top or 211 
bottom 1% of the ratio of energy intake to estimated energy required(21)) were 212 
excluded (n=10 066). After these exclusions, the prsent analysis included 333 919 213 
women. 214 
Hormonal and reproductive factors 215 
Self-reported menstrual factors, and exogenous hormone use included: age at menarche 216 
(<12, 12, 13, 14, >14 years), history (yes/no) and duration of OC use (non-user, >0-≤1, 217 
>1-5, >5-10 years), menopausal status at baseline (premenopausal: ≥9 cycles over the 218 
past 12 months, perimenopausal: <9 cycles, natural menopause in case of no menses, 219 
and surgical menopause in case of bilateral oophorectomy), age at natural menopause 220 
(surgical menopause were excluded, ≤46, 47-49, 50-52, ≥53 years) , age at any 221 




duration (non-user, >0-≤1.25, >1.25-4, >4 years), type of MHT (oestrogen alone, 223 
progestin alone, or oestrogen plus progestin), oophrectomy (yes/no), hysterectomy 224 
(yes/no), and calculated cumulative duration of menstrual cycling. Cumulative duration 225 
of menstrual cycling (in years) is an accepted proxy f r total endogenous exposure and 226 
was calculated as follows(14,22): for postmenopausal women, it was the difference 227 
between the age at menopause and the age at menarch minus the total time pregnant 228 
(number of full-term pregnancies (FTP) x 9 months, due to the absence of menstrual 229 
cycles of 9 months for each pregnancy). For pre- and perimenopausal women, 230 
cumulative duration of menstrual cycling was the difference between age at recruitment 231 
and age at menarche minus the total time pregnant. Total time taking OCs was 232 
subtracted from cumulative duration of menstrual cycling for pre-, peri-, and 233 
postmenopausal women. To assess for hormonal changes during pregnancy and 234 
exogenous hormones through OC use, those models were additionality adjusted for 235 
number of FTP and OC-use. 236 
Self-reported reproductive history included: parity (yes/no), number of FTP (including 237 
livebirths and stillbirths; 0, 1, 2, 3, 4, ≥5), age at first FTP (in parous women; ≤20, 21-238 
13, 24-25, 26-30, ≥30 years), number of induced (never pregnant, 0, 1, ≥2) and 239 
spontaneous abortions (never pregnant, 0, 1, ≥2) breastfeeding (in parous women; 240 
yes/no), and duration of breastfeeding (in parous women who breastfeed; 0>-≤3, >3-12, 241 
>12 months).  242 
Bladder cancer assessments 243 
Incident bladder cancers were identified through population registries (Denmark, Italy, 244 
The Netherlands, Norway, Spain, Sweden, and United Kingdom) and active follow-up, 245 
including use of health insurance records, hospital registries, and direct contacts with 246 




follow-up for UC was completed between December 2011 and December 2013, 248 
depending on the centre. 249 
Bladder cancers were defined by ICD-O-3, including first invasive cancer (coded C67 250 
based) and UC (morphology codes 812*–813*)(23). Only i cident UC was included in 251 
the present analyses; since it represents 95% of all bladder cancers. Definitions of UC 252 
subtype classifications are heterogeneous in the literature. In previous EPIC studies, UC 253 
was classified by pathology reports as aggressive (pT1 and higher or carcinoma in situ 254 
(CIS) or World Health Organization (WHO) Grade 3), and non-aggressive (pTa Grade 1 255 
and 2)(23). We also analysed UC by tumour grade (using WHO-defined Grades 2 and 3 256 
as “high-grade” and Grade 1 as “low-grade”)(24). Finally, in centres where tumour 257 
stage information was available (available in all centres except San Sebastian, United 258 
Kingdom, Greece, Malmö, and Norway), we analysed UC restricted to non-muscle 259 
invasive subtype (pT1, pTa, or CIS).  260 
Statistical analysis 261 
To evaluate associations between hormonal factors and UC risk, Cox proportional 262 
hazards regression was used to estimate hazard ratios (HRs) and 95% confidence 263 
intervals (95%CI). Ordinal variables were scored an trend tests were calculated on 264 
these scores, “unknown” category was excluded for trend test calculation. Estimations 265 
of “unknown” categories were provided when more than 10% of the cases were 266 
classified as “unknown”. Age was used as the time scale, with age at recruitment as the 267 
entry time, and age at the date of UC or the end of follow-up (whichever came first) as 268 
the exit time. Additional models were performed to describe the risk of UC by tumour 269 
aggressiveness, tumour grade (using the Wald test statistic to assess the heterogeneity of 270 
the risk between outcomes using the SAS macro %subtype(25)), and non-muscle 271 




study centre. Stratified models by center allowed us to give each center its own baseline 273 
hazard, thus the variation in menstrual and reproductive history, hormone use, and 274 
cancer patterns across centers were included in the model. Further, stratified by age 275 
provided left truncation of the data (the risk of developing the outcomes of interest was 276 
only included during the follow-up). Finally, these stratified models assumed 277 
proportional hazard between the centers. All models were adjusted for smoking status 278 
and intensity at baseline (never-smokers, current smokers ≤15 cigarettes/day, current 279 
smokers >15 cigarettes/day, ex-smokers ≤10 years, ex-smokers >10 years, current: 280 
pipe/cigar/occasional cigarette smokers, current/former: missing intensity, and 281 
unknown), and fruit and vegetable intakes (both entered as continuous variable g/d) (4), 282 
which change estimate effect of the hormone variables y more than >10%. Physical 283 
activity and body mass index (BMI) were not included as adjustment covariates because 284 
they did not change effect estimates >10%. Occupations with potential exposure to 285 
bladder carcinogens are potential confounder given th  established effect of a number of 286 
chemicals and substances (e.g. heavy metal, dyes, and polycyclic aromatic 287 
hydrocarbons [PAHs]) on sex hormones levels among healt y women(26–28). Other 288 
potential confounders were occupations with potential exposure to bladder carcinogens. 289 
To adjust models for occupational exposure a dichotom us score (yes/no) was defined, 290 
where it was coded as “yes” if the participant worked in occupations with potential 291 
exposure to heavy metals (present in foundries, in metal industries, and in occupations 292 
related to welding, turning and electroplating), aromatic amines (present in, e.g. dye 293 
production, textile and leather dying, and hairdresser ), PAHs (associated with 294 
refineries, asphalt work, the transport sector, and car repair stations), and environmental 295 
tobacco smoking (particularly elevated for workers in bars and restaurants), detailed 296 




included in the multivariable-adjusted models because <7% of women worked in a 298 
job/occupation with potential exposure to bladder carcinogens, and adjusting for 299 
occupational exposure did not change any estimated HRs. To evaluate all identified 300 
factors in one model, mutually-adjusted models were valuated. The proportional 301 
hazard assumption was checked using Schoenfeld resiual . Also, all the time-302 
dependent variables (interactions of predictors and time) were included in the mutually-303 
adjusted model and evaluated. Restricted cubic splines with 3-5 knots were used to 304 
explore linearity in the trend in the risk with number of FTP. Akaike information 305 
criterion (AIC) was used to select the best representation of the relation between 306 
number of FTP (among parous women) and UC risk (Supplemental Figure 1). 307 
Modification of the HRs by tobacco use at baseline ( ver, former, and current) was 308 
evaluated using a likelihood ratio test (LRT). Joint effect variables (with a common 309 
referent group) for tobacco with each variable included in the final model were also 310 
evaluated.  311 
Sensitivity analyses were performed in never smokers to reduce the likelihood of 312 
residual confounding by smoking at baseline. Finally, to address possible changes in the 313 
reproductive history during the follow-up, a sensitivity analysis including only women 314 
with completed reproductive history (peri-/postmenopausal women at recruitment) was 315 
performed for the final model. 316 
All statistical tests were two-sided and evaluated at α-level 0.05. All analyses were 317 
performed using SAS v. 9.4 (Cary, North Carolina, USA). 318 
Results: 319 




After a median follow-up time of 15 years, 529 UC cases were identified including 146 321 
non-aggressive tumours, 230 aggressive tumours, and 153 with unknown tumour 322 
aggressiveness; and among the 529 cases, there were 80 low-grade tumours, 233 high-323 
grade tumours, and 216 with unknown tumour grade. The median age at recruitment 324 
was 51 years (y) (25th and 75th percentile (p25-p75): 45-58-y) for the whole cohort and 325 
58-y (p25-p75: 52-63-y) for UC cases. The median age at diagnosis was 68-y (p25-p75: 326 
62-74-y). Baseline characteristics of participants by country are presented in Table 1. 327 
Menstrual factors, and exogenous hormone use  328 
Age at menarche, cumulative duration of menstrual cycling, history and duration of OC 329 
use, age at natural menopause, oophorectomy, and hysterectomy showed no association 330 
with UC risk (Table 2, Table 3). Elevated and statiically significant HRs for UC were 331 
observed for postmenopausal status (natural or surgical) compared to premenopausal 332 
status (HRpostnaturalvspre: 1.88; 95%CI, 1.09-3.25; HRpostsurgicalvspre: 2.15; 95%CI, 1.10-333 
4.20) (Table 1). MHT use in peri-/postmenopausal women (natural or surgical) was 334 
positively associated with overall UC independently of the duration of MHT use (Table 335 
3). For the 67% (n=52,892, 82 cases) of women with information on formulation of 336 
MHT available, 25% (n=13,123, 32 cases) took oestrogen alone (HR: 1.43; 95%CI: 337 
0.97-2.10). No association was observed for use of oestrogen plus progestin MHT 338 
formulations (HR: 1.08; 95%CI, 0.77- 1.51) (Table 3). 339 
Reproductive factors 340 
There was a statistically significant inverse association for number of FTP and UC risk 341 
(HR3vs1FTP: 0.70; 95%CI, 0.52-0.94; HR≥5vs1FTP: 0.46; 95%CI, 0.25-0.88; P-trend in 342 
parous women only = 0.008). No statistically significant associations were observed for 343 




Mutually-adjusted Cox proportional hazards regression for UC  345 
Models included number of FTP and menopausal status, where peri-/postmenopausal 346 
women were further classified by MHT history. Statistically significant inverse 347 
associations between number of FTP and UC risk were observed (HR3vs1FTP: 0.70; 348 
95%CI, 0.52-0.94; HR≥5vs1FTP: 0.48; 95%CI, 0.25-0.90; P-trend in parous women only 349 
0.010) (Table 5). Further, the HR for peri-/postmenopausal MHT-users compared to 350 
peri-/postmenopausal women never-users was 1.27 (95%CI, 1.03-1.57) (Table 5).  351 
Study of the heterogeneity of the risk between non-aggressive tumours and 352 
aggressive tumours 353 
MHT-use was positively associated with risk of non-aggressive UC (HRyesvsno: 1.93; 354 
95%CI, 1.29- 2.87). Parity was inversely associated with non-aggressive UC risk 355 
(HRyesvsno: 0.59; 95%CI, 0.39- 0.90). Natural and surgical menopause were statistically 356 
significantly associated with risk of aggressive UC (HRnaturalvspre: 2.47; 95%CI, 1.01-357 
6.03; HRsurgicalvspre: 3.25; 95%CI, 1.18-8.97) (Supplemental Table 1). Despite these 358 
statistically significant individual associations, statistically significant heterogeneity of 359 
the risk for menstrual factors and exogenous hormone use by tumour aggressiveness 360 
was not observed for each individual model, and for the mutually-adjusted model (all 361 
Phet-value > 0.05). 362 
Study of the heterogeneity of the risk between low-grade tumours and high-grade 363 
tumours 364 
MHT-use was positively associated with low-grade tumo rs (HR: 2.37; 95%CI, 1.37- 365 
4.12), while the number of spontaneous abortions (comparisons based on 17 women in 366 
the referent group) was statistically significant ad inversely associated with the risk of 367 




0.44; 95%CI, 0.26- 0.75; comparisons based on 18 women in the referent group). No 369 
associations were observed between hormonal factors and high-grade UC risk 370 
(Supplemental Table 1). 371 
Statistically significant heterogeneity in the risk estimates by tumour grade was 372 
observed in relation to the number of spontaneous abortions (Phet-value=0.026) and 373 
parity (Phet-value=0.011). Finally, once the identified variables were included in one 374 
model, estimations of the risk were similar by tumour grade (Phet-value=0.079). 375 
Risk estimation between hormonal and reproductive factors and non-muscle 376 
invasive UC 377 
Positive association was observed between MHT-users and non-muscle invasive UC 378 
risk (HR: 1.38; 95%CI, 1.01-1.90), especially in women which treatment’s formulation 379 
was oestrogen alone (HR: 1.90; 95%CI, 1.15-3.13) (Supplemental Table 1).  380 
Modification of the HRs by tobacco 381 
No evidence for modification of HRs for each factor and UC by cigarette smoking 382 
status was found (all likelihood ratio statistics P-value>0.05) with the exception of 383 
induced abortions (P-value=0.028). Different estimations of the HR of the number of 384 
induced abortions were observed by smoking status. While no association between 385 
number of induced abortions and the risk of UC was ob erved; HR for never smoking 386 
women with at least 2 induced abortions compare to 0 abortions was 2.52 (95%CI: 387 
1.33- 4.78, P-trend = 0.012) (Supplemental Table 2).  388 
No modification of HRs by cigarette smoking status in the mutually-adjusted model was 389 
observed. Nonetheless, the higher risk of MHT-use was only observed in peri-390 




95%CI: 1.10, 2.21) (Supplemental Table 3). No statiically significant associations 392 
were observed when joint-effect variables for tobacco and FTP, and tobacco and 393 
menopausal status were evaluated. 394 
Sensitivity analyses 395 
In general, patterns of HRs did not change substantially when we restricted analyses to 396 
the subgroup of never smokers (Supplemental Table 2 and Table 5), or in the subgroup 397 
of participants who were peri-/postmenopausal at recruitment (Table 5). In never 398 
smokers, no association between MHT-use and UC risk was observed in the final 399 
mutually adjusted model (Table 5). 400 
Discussion: 401 
The present analyses based on 529 women, showed evidence that women who had 402 
experienced more than one birth are at lower risk of developing UC compared to 403 
uniparous women; further, we observed evidence of an inverse trend between UC risk 404 
and number of births. No associations were observed for the remaining menstrual 405 
factors, reproductive history variables, or exogenous hormone use variables. We 406 
observed no evidences of differences in the estimations of UC risk by the number of 407 
full-term pregnancies or other menstrual factors, reproductive history factor, or 408 
exogenous hormone use according to tumour characteristics (based on tumour grade and 409 
tumour stage).  410 
Previous studies(11,12,18) and two meta-analyses(10,17) observed a reduced risk of UC 411 
in parous women, independent of the number of births(10,11,13,14,16–18). Nearly all 412 
these studies used “nulliparous” as the referent category(11,13,14,16,17). Nulliparous 413 




without fertility problems. In our study, “one birth” was used as a referent category, and 415 
we found a linear trend of decreasing UC risk with increasing number of FTP. This 416 
reduction in risk with increasing FTP was also observed in never-smokers. The 417 
observed trend in our study was similar to the trend reported by Weibull et al. (HR for 418 
≥3 vs. 1 FTP: 0.76; 95%CI: 0.68-0.86)(12).  419 
Women experience several hormonal changes during pre nancy, including an increase 420 
in oestrogen and progesterone levels(30). An animal study observed that these increased 421 
levels, particularly progesterone levels, may be related with changes in the bladder 422 
structure related to greater bladder capacity and compliance(31). Further, it has been 423 
shown that oestrogen receptors (ER) and progesterone receptors (PR), that mediate 424 
oestrogen and progesterone levels, are expressed in both normal and cancerous 425 
urothelial cells(32,33). ERs have different roles in cancer biology, in general ER-α has 426 
been related with cell growth, while ER-β has been suggested to act as a suppressor of 427 
tumour growth, thus ER-α and ER-β may have opposing effects on cellular 428 
processes(34). It has been observed that ER-β is the dominant receptor expressed in 429 
urothelial carcinoma cells(8,32). Few studies have be n done in relation to ERs and 430 
progesterone in urothelial carcinoma cells, but it has been suggested that progesterone 431 
suppresses ER expression during pregnancy(35). Consequently, it can be hypothesized 432 
that these increased levels of oestrogen and progesterone may reduce UC risk in parous 433 
women(9–12,17,36). 434 
Two previous studies have examined the association between induced abortions and the 435 
risk of UC (15,37). These two case-control studies did not observe that the number of 436 
induced abortions was associated with UC risk. Our results on never-smokers were 437 
based on a small number of cases, and in view of the large number of associations 438 




due to chance. 440 
It has been hypothesized that earlier age at menopause increases UC risk due to lower 441 
levels of oestrogen after menopause(14). Earlier ag at menopause (natural or surgical) 442 
was associated with an increased risk of UC in a meta-analysis(17), that included 4 443 
case-control studies and 3 cohort studies. We observed no association between earlier 444 
age at menopause and UC, in agreement with other recent prospective cohort 445 
studies(10,11,18). 446 
The higher UC risk we observed in peri-/postmenopausal MHT users, when compared 447 
to peri-/postmenopausal non-users, is inconsistent with previous studies which found no 448 
relation(10,17,18). Our results and previous studies showed no dose-response by years 449 
of MHT-use(10,11,13,16,18). The WHI found no influenc  of the formulation of MHT 450 
on the risk of UC (results for oestrogen: n=136 cases; HR: 0.93; 95%CI: 0.74-1.17; 451 
results for oestrogen plus progestin: n=103 cases; HR: 1.05; 95%CI: 0.81-1.36)(18). A 452 
meta-analysis (based on 4 cohort studies) of MHT by formulation (oestrogen or 453 
oestrogen plus progestin) showed a 39% decreased UC risk in users of oestrogen plus 454 
progestin (n=84 cases; RR: 0.61; 95%CI: 0.47-0.78), and no effect for users of 455 
oestrogen alone (n=217 cases; RR: 1.03; 95%CI: 0.87-1.24)(11). Our results, based on 456 
smaller sample sizes (52 UC for oestrogen, and 30 UC for oestrogen plus progestin), 457 
were in agreement with those from the WHI, however we observed a positively 458 
statistically significant estimation in current-smokers who used oestrogen alone or 459 
reported unknown type of MHT. Since we observed no association in never-smokers, 460 
and the MHT effect (overall and by formulation) only remained significant in current-461 
smokers, residual confounding from tobacco smoking a d possible chance are a likely 462 




Our study strengths include its prospective cohort design and a relatively large number 464 
of incident cases from 10 European countries, which allowed us to investigate 465 
associations by strata of smoking status. To our knowledge, this is the first study on 466 
menstrual factors, reproductive history, hormone us, and UC risk that includes 467 
information on tumour classification. However, non-muscle invasive UC classification 468 
was not available in San Sebastian, Oxford, Cambridge, Malmö, and Norway centres.   469 
One potential weakness of our analysis is that information on reproductive history and 470 
hormone use was available only at cohort enrolment; however, we noted that 78.7% of 471 
the cases were postmenopausal at recruitment, so repr ductive history was essentially 472 
complete for most participants. We performed sensitivity analyses restricted to 473 
postmenopausal women, whose reproductive exposures were unlikely to change. We 474 
observed similar results for the final mutually-adjusted model in the analysis restricted 475 
to postmenopausal women as we observed for all study participants, suggesting our 476 
results were unlikely to be affected by any changes in reproductive history after 477 
enrolment. Another potential weakness of our study was the large number of missing 478 
values in the MHT variables (duration and formulation). Also, information on MHT 479 
was not periodically updated, and therefore, we could not evaluate risk in women who 480 
started using MHT or who modified their use after en olment. Further, tumour grade 481 
and tumour aggressiveness had a large number of missing values which could bias HR 482 
estimates. We would also like to highlight that information on smoking habits, and fruit 483 
and vegetables intakes were not periodically updated, so could not evaluate changes 484 
after baseline for any variables. Results from the sensitivity analyses in never smoking 485 
women showed that, except for MHT, our results were not affected by residual 486 
confounding by smoking status. Finally, we could not consider occupational exposure in 487 




exposure was available for 32% (n=169) of UC cases; of which 10% (n=17) reported 489 
jobs considered at risk. Despite this, a sensitivity analysis was performed including 490 
occupational exposures in the final UC model and similar HR estimates for menopausal 491 
status, MHT-use, and number of full-term pregnancies w re observed.  492 
Conclusion: 493 
Our results confirm the increasing benefit of each birth after the first on UC risk. More 494 
studies on number of FTP are needed to elucidate the putative protective effects of 495 
parity. Further investigations of the role of perinatal hormonal changes and how these 496 
changes may affect ER and PR levels and urothelial cells in the bladder are needed. 497 
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Table 1: Baseline characteristics of women in the EPIC cohort by country 647 
  
Cohort 
(n= 333 919) 
France 
(n= 67 403) 
Italy  
(n= 30 513) 
Spain 
(n= 24 850) 
United  
Kingdom 
(n= 52 566) 
The  
Netherlands 
(n= 26 912) 
Greece 
(n= 15 233) 
Germany 
(n= 27 379) 
Sweden 
(n= 26 368) 
Denmark 
(n= 28 720) 
Norway 
(n= 33 975) 
Urothelial Carcinoma cases 529 40 72 32 68 80 7 25 105 80 20 
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Smoking status and intensityb            
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Diabetes b, yes 
7 422 
(2.4) 



















Numbers may not sum to totals due to missing values 648 
a Median (percentile 25th and percentile 75th) // b n (%) // c Available in Spain, Cambridge, Greece, Germany, Denmark, and Norway // d Job exposure was coded as “yes” if the participant worked 649 




Table 2: Multivariable-adjusted models for each individual menstrual factor in relation to UC risk in 651 




HR (95%CI) a P-trend 
Age at menarche, years  
  
 
<12 678 236 64 (12.1) 1.00 (referent) 0.845 
12 955 271 103 (19.5) 1.10 (0.80- 1.51)  
13 1 166 665 128 (24.2) 1.05 (0.78- 1.43)  
14 976 383 108 (20.4) 0.92 (0.67- 1.26)  
>14 718 342 113 (21.4) 1.07 (0.78- 1.48)  
Cumulative duration of menstrual 







<23 960 018 72 (13.6) 1.00 (referent) 0.924 
23- <30 693 105 96 (18.2) 1.01 (0.73- 1.39)  
30- <35 920 740 108 (20.4) 0.87 (0.63- 1.21)  
≥35 805 979 142 (26.8) 1.00 (0.71- 1.40)  
Unknown 1 011 360 111 (21.0) 1.05 (0.74- 1.48)  
Menopausal status  
  
 
Premenopausal 1 654 703 49 (9.3) 1.00 (referent)  
Perimenopausal 896 065 64 (12.1) 1.32 (0.77- 2.8)  
Natural postmenopausal 1 992 700 394 (74.5) 1.88 (1.09- 3.25)  
Surgical postmenopuasal 117 733 22 (4.2) 2.15 (1.10- 4.20)  
Age at natural menopause, years c  
  
 
≤46 385 834 85 (21.6) 1.17 (0.87- 1.58) 0.527 
47- 49 337 177 68 (17.3) 1.08 (0.79- 1.48)  
50 - 52 509 460 97 (24.6) 1.00 (referent)  
≥53 305 850 79 (20.1) 1.33 (0.99- 1.80)  
Unknown 454 379 65 (16.5) 1.21 (0.86- 1.70)  
Age at any menopause, years     
≤46 450 220 100 (24.0) 1.21 (0.91- 1.60) 0.853 
47- 49 360 268 70 (16.8) 1.04 (0.76- 1.42)  
50 - 52 527 478 101 (24.3) 1.00 (referent)  
≥53 315 160 80 (19.6) 1.31 (0.97- 1.77)  
Unknown 457 307 65 (15.6) 1.20 (0.86- 1.68)  
Oophorectomy d     
No 3 407 081 344 (76.1) 1.00 (referent)  
Unilateral 145 533 28 (6.2) 1.32 (0.90- 1.95)  
Bilateral 131 175 23 (5.1) 1.12 (0.73- 1.72)  
Unknown 965 580 55 (12.2) 0.91 (0.47- 1.78)  
Hysterectomy d  
  
 
No 3 640 275 344 (76.1) 1.00 (referent)  
Yes 472 260 76 (16.8) 1.09 (0.84- 1.40)  
UC: Urothelial Carcinoma // OC: oral contraceptive // Numbers may not sum to totals due to missing values 653 
Estimation of “Unknown” category is provided when more than 10% of the cases are classified as “Unknown”. 654 
a Cox proportional hazards model stratified by centre and age at recruitment and adjusted by smoking status and intensity, fruits 655 
and vegetables intake. 656 
b Cox proportional hazards model stratified by centre and age at recruitment and adjusted by smoking status and intensity, 657 
fruits and vegetables intake, OC use, and full-term p egnancies 658 
c Women who had surgical menopause were excluded. 659 
d Available in all centres except Malmö. 660 
 661 




Table 3: Multivariable-adjusted models for each individual exogenous hormone use in relation to UC 663 





HR (95%CI) a P-trend 
Use of OC  
  
 
No 1 859 302 278 (52.6) 1.00 (referent)  
Yes 2 668 828 239 (45.2) 0.93 (0.77- 1.14)  
Unknown 133 072 12 (2.3) 
 
 
Duration OC use, years   
  
 
No 1 859 302 278 (52.6) 1.00 (referent) 0.259 
>0- ≤1 495 753 34 (6.4) 0.70 (0.49- 1.01)  
>1- 5 780 263 63 (11.9) 0.94 (0.71- 1.26)  
>5- 10 594 859 69 (13.0) 1.22 (0.92- 1.63)  
>10 546 567 51 (9.6) 0.82 (0.59- 1.13)  
Unknown duration 251 386 22 (4.2) 
 
 
Missing use of OC 133 072 12 (2.3)   
Use of MHT b  
  
 
No 1 740 862 247 (51.5) 1.00 (referent)  
Yes 1 072 357 172 (35.8) 1.28 (1.04- 1.58)  
Unknown 193 278 61 (12.7) 1.32 (0.90- 1.95)  
Duration MHT use, years b     
No 1 740 862 247 (51.5) 1.00 (referent) 0.152 
>0- ≤1.25 321 348 51 (10.6) 1.33 (0.98- 1.81)  
>1.25-4 336 578 47 (9.8) 1.37 (0.99- 1.90)  
>4 310 366 56 (11.7) 1.27 (0.93- 1.73)  
Unknown duration 104 065 18 (3.8)   
Unknown use of MHT 193 278 61 (12.7) 1.03 (0.74- 1.43)  
Type of MHT b, c     
Non-users of MHT 1 527 202 215 (58.0) 1.00 (referent)  
Oestrogen alone 178 339 32 (8.6) 1.43 (0.97- 2.10)  
Oestrogen + Progestin 527 153 50 (13.5) 1.08 (0.77- 1.51)  
Unknown type of MHT 329 620 74 (20.0) 1.37 (1.04- 1.81)  
UC: Urothelial Carcinoma // OC: oral contraceptive // MHT: menopause hormone therapy 666 
Estimation of “Unknown” category is provided when more than 10% of the cases are classified as “Unknown”.  667 
a Cox proportional hazards model stratified by centre and age at recruitment and adjusted by smoking status and intensity, 668 
fruits and vegetables intake. 669 
b In peri- and postmenopausal (natural or surgical). 670 




Table 4: Multivariable-adjusted models for each individual reproductive factor in relation to UC 






HR (95%CI) a P-trend 
Parity     
No  686 624 73 (13.8) 1.00 (referent)  
Yes 3 774 138 440 (83.2) 0.87 (0.68- 1.12)  
Number of full-term pregnancies b     
0 c 686 624 69 (13.5) 0.92 (0.67- 1.25) 0.008d 
1 663 853 99 (19.4) 1.00 (referent)  
2 1 787 539 192 (37.6) 0.80 (0.62- 1.02)  
3 845 995 89 (17.4) 0.70 (0.52- 0.94)  
4 253 868 35 (6.9) 0.79 (0.53- 1.18)  
≥5 110 467 11 (2.2) 0.47 (0.25- 0.88)  
Age at first full-term pregnancy, years d       
≤20  546 150 68 (15.5) 1.00 (referent) 0.688 
21- 23  1 001 554 119 (27.1) 1.03 (0.76- 1.40)  
24- 25  742 124 73 (16.6) 0.86 (0.61- 1.20)  
26- 30  1 086 162 139 (31.6) 1.03 (0.76- 1.39)  
≥30  382 435 40 (9.1) 0.89 (0.59- 1.32)  
Breastfeeding d, e       
 No 523 624 57 (14.1) 1.00 (referent)  
 Yes 2 984 829 341 (83.8) 0.85 (0.64- 1.14)  
Duration of breastfeeding, all pregnancies, 
months e, f 
      
>0-≤3  854 602 115 (33.7) 1.00 (referent) 0.092 
>3- 12 1 327 975 142 (41.6) 0.73 (0.56- 0.95)  
>12  771 517 79 (23.2) 0.78 (0.55- 1.09)  
Induced abortions g     
Never pregnant 483 030 48 (12.4) 1.19 (0.91- 1.56) 0.759 
0 2 466 069 269 (69.7) 1.00 (referent)  
1 404 767 45 (11.7) 1.12 (0.81- 1.56)  
≥2 176 646 19 (4.9) 1.01 (0.62- 1.64)  
P-trend     
Spontaneous abortions h     
Never pregnant 508 626 56 (12.1) 1.14 (0.85- 1.52) 0.497 
0 2 469 123 295 (63.7) 1.00 (referent)  
1 587 558 78 (16.9) 1.10 (0.86- 1.42)  
≥2 200 186 27 (5.8) 1.05 (0.71- 1.56)  
Infertility problems i     
No 2 872 888 255 (83.3) 1.00 (referent)  
Yes 142 531 16 (5.2) 1.61 (0.97- 2.69)  
Unknown 151 702 35 (11.4) 1.72 (0.24- 12.51)  
UC: Urothelial Carcinoma // Numbers may not sum to toals due to missing values 
Estimation of “Unknown” category is provided when more than 10% of the cases are classified as “Unknown”.  
a Cox proportional hazards model stratified by centre and age at recruitment and adjusted by smoking status and 
intensity, fruits and vegetables intake. 
b Available in all centres except Bilthoven. 
c
 Including nulliparous women and women without full-term pregnancies.  
d In parous women. 
e Available in all centres except Bilthoven and Umeå. 
f In parous women who has ever breastfed. 
g Available in all centres except Bilthoven, Malmö, Umeå, and Norway. 
h Available in all centres except Bilthoven, Umeå, and Norway. 




Table 5: Mutually-adjusted models for menopause statu , MHT, and parity in relation to UC risk in EPIC women. 




HR (95%CI) a P-trend 
Cases (%) 
n=195 
HR (95%CI) b P-trend 
Cases (%) 
n=195 
HR (95%CI) b P-trend 
Menopausal status & use of MHT       
   
Premenopausal  49 (9.26) 0.73 (0.43- 1.22)  18 (9.23) 1.23 (0.52- 2.43)     
Peri-/Postmenopausal & non-users of MHT 247 (46.7) 1.00 (referent)  105 (53.9) 1.00 (referent)  247 (51.5) 1.00 (referent)  
Peri-/Postmenopausal & users of MHT 172(32.5) 1.27 (1.03- 1.57)  52 (26.7) 1.02 (0.71- 1.47)  172 (35.8) 1.28 (1.04- 1.59)  
Peri-/Postmenopausal & unknown MHT-use 61 (11.5) 1.35 (0.88- 2.07)  20 (10.26) 1.12 (0.53- 2.39)  61 (12.7) 1.34 (0.89- 2.02)  
Number of full-term pregnancies c   
       
0 d 69 (13.5) 0.92 (0.67- 1.25) 0.010e 19 (9.7) 0.72 (0.40- 1.29) 0.069e 66 (14.1) 1.03 (0.73- 1.39) 0.008 e 
1 99 (19.4) 1.00 (referent)  32 (16.4) 1.00 (referent)  88 (18.8) 1.00 (referent)  
2 192 (37.6) 0.80 (0.62- 1.02)  83 (42.6) 0.95 (0.63- 1.45)  171 (36.5) 0.79 (0.61- 1.03)  
3 89 (17.4) 0.70 (0.52- 0.94)  39 (20.0) 0.85 (0.52- 1.37)  82 (17.5) 0.71 (0.52- 0.97)  
4 35 (6.9) 0.80 (0.54- 1.19)  9 (4.6) 0.57 (0.27- 1.21)  35 (7.5) 0.85 (0.57- 1.27)  
≥5 11 (2.2) 0.48 (0.25- 0.90)  5 (2.6) 0.49 (0.18- 1.29)  11 (2.4) 0.51 (0.27- 0.97)  
UC: Urothelial Carcinoma // MHT: menopausal hormone th rapy // Numbers may not sum to totals due to missing values 
Estimation of “Unknown” category is provided when more than 10% of the cases are classified as “Unknown”.  
a Cox proportional hazards model stratified by centre and age at recruitment and adjusted by menopausal status and MHT, number of full-term pregnancies, smoking status and intensity, fruits 
and vegetables intake. 
b Cox proportional hazards model stratified by centre and age at recruitment and adjusted by menopausal status and MHT, number of full-term pregnancies, fruits and vegetables intake. 
c Available in all centres have information except Bil hoven. 
d Including nulliparous women and women without full-term pregnancies. 





Supplemental Figure 1: Restricted cubic splines plots of the association between number of full-
term pregnancies and UC risk in EPIC women. 
 
Cox proportional hazards model stratified by centre and age at recruitment and adjusted by menopausal status and 




Supplemental Table 1: Reproductive factors, menstrual, menopausal factors, and exogenous hormone use in relation to UC by aggressiveness, grade, and non-












 Cases(%) HR(95%CI) 
b Cases(%) HR(95%CI) b Cases(%) HR(95%CI) b Cases(%) HR(95%CI) b Cases(%) HR(95%CI) b 
Age at menarche, years           
<12 12(8.4) 1.00(referent) 33(14.4) 1.00(referent) 10(12.5) 1.00(referent) 25(10.7) 1.00(referent) 31(15.7) 1.00(referent) 
12 26(17.8) 1.39(0.70-2.76) 45(19.6) 0.96(0.61-1.51) 7(8.8) 0.47(0.18-1.24) 51(21.9) 1.41(0.87-2.29) 37(18.7) 0.85(0.53-1.38) 
13 37(25.3) 1.64(0.85-3.17) 55(23.9) 0.91(0.59-1.41) 23(28.8) 1.29(0.61-2.75) 60(25.8) 1.36(0.85-2.19) 41(20.7) 0.76(0.48-1.23) 
14 36(24.7) 1.74(0.90-3.39) 45(19.6) 0.74(0.47-1.18) 20(25.0) 1.26(0.58-2.76) 50(21.5) 1.23(0.75-2.00) 45(22.7) 0.87(0.54-1.39) 
>14 32(21.9) 1.80(0.91-3.57) 47(20.4) 0.81(0.51-1.29) 19(23.8) 1.46(0.65-3.24) 41(17.6) 1.13(0.68-1.89) 42(21.2) 0.90(0.55-1.45) 
Unknown 3(2.1)  5(2.2)  1(1.3)  6(2.6)  2(1.0)  
P-trend  0.075  0.188  0.057  0.903  0.796 
Cumulative duration of 
menstrual cycling, accounting 
for OC use, years c 
          
<23 17(11.6) 1.00(referent) 29(12.6) 1.00(referent) 9(11.3) 1.00(referent) 28(12.0) 1.00(referent) 31(15.7) 1.00(referent) 
23-<30 31(21.2) 1.29(0.70-2.36) 41(17.8) 1.09(0.67-1.78) 18(22.5) 1.59(0.69-3.65) 44(18.9) 0.98(0.60-1.59) 36(18.2) 0.95(0.58-1.55) 
30-<35 32(21.9) 1.14(0.62-2.12) 47(20.4) 0.94(0.58-1.53) 19(23.8) 1.48(0.63-3.46) 42(18.0) 0.74(0.45-1.22) 39(19.7) 0.75(0.46-1.23) 
≥35 37(25.3) 1.14(0.61-2.12) 63(27.4) 1.17(0.73-1.87) 21(26.2) 1.57(0.66-3.71) 65(27.9) 0.99(0.61-1.61) 52(26.3) 0.89(0.55-1.45) 
Unknown 29(18.9) 1.19(0.60-2.35) 50(21.7) 1.01(0.61-1.67) 13(16.3) 1.53(0.59-3.98) 54(23.2) 1.01(0.60-1.71) 40(20.2) 0.72(0.43-1.22) 
P-trend  0.396  0.610  0.348  0.982  0.674 
Use of OC           
No 80(54.8) 1.00(referent) 123(53.5) 1.00(referent) 38(47.5) 1.00(referent) 137(58.8) 1.00(referent) 96(48.5) 1.00(referent) 
Yes 65(44.5) 0.79(0.54-1.15) 103(44.8) 0.90(0.67-1.21) 42(52.5) 0.98(0.59-1.63) 94(40.3) 0.80(0.59-1.08) 98(49.5) 1.03(0.76-1.42) 




Duration OC use, years           
No 80(54.8) 1.00(referent) 123(53.5) 1.00(referent) 38(47.5) 1.00(referent) 137(58.8) 1.00(referent) 96(48.5) 1.00(referent) 
>0-≤1 6(4.1) 0.40(0.17-0.82) 19(8.3) 0.84(0.51-1.39) 5(6.3) 0.65(0.25-1.70) 14(6.0) 0.57(0.32-1.00) 16(8.1) 0.84(0.49-1.45) 
>1-5 16(11.0) 0.79(0.45-1.40) 24(10.4) 0.85(0.54-1.35) 10(12.5) 0.94(0.45-1.98) 19(8.2) 0.65(0.39-1.07) 24(12.1) 1.09(0.68-1.75) 
>5-10 19(13.0) 1.03(0.60-1.78) 28(12.2) 1.12(0.72-1.74) 15(18.8) 1.53(0.79-2.99) 25(10.7) 0.96(0.61-1.52) 28(14.1) 1.41(0.90-2.22) 
>10 17(11.6) 0.86(0.48-1.53) 22(9.6) 0.74(0.46-1.21) 6(7.5) 0.41(0.20-1.31) 25(10.7) 0.93(0.58-1.50) 22(11.1) 0.93(0.57-1.54) 
Unknown duration 7(4.8)  10(4.4)  6(7.5)  11(4.7)  8(4.0)  
Unknown use of OC 1(0.7)  4(1.7)    2(0.9)  4(2.0)  
P trend  0.769  0.469  0.712  0.549  0.809 
Menopausal status           
Premenopausal 18(12.3) 1.00(referent) 15(6.5) 1.00(referent) 12(15.0) 1.00(referent) 23(9.9) 1.00(referent) 15(7.6) 1.00(referent) 
Perimenopausal 21(14.4) 0.87(0.37-2.04) 22(9.6) 1.64(0.67-4.00) 15(18.8) 1.19(0.39-3.58) 25(10.7) 1.56(0.71-3.43) 145(73.2) 2.05(0.83-5.03) 
Natural postmenopausal 102(69.9) 1.26(0.52-3.02) 180(78.3) 2.47(1.01-6.03) 51(63.8) 1.16(0.35-3.81) 175(75.1) 1.60(0.60-4.22) 26(13.1) 1.59(0.66-3.81) 
Surgical postmenopuasal 5(3.4) 1.11(0.33-3.75) 13(5.7) 3.25(1.18-8.97) 2(2.5) 0.80(0.13-4.81) 10(4.3) 1.08(0.50-2.36) 12(6.1) 2.64(0.94-7.43) 
Age at natural menopause, 
years d 
          
≤46 21(20.6) 1.14(0.64-2.05 39(21.7) 1.14(0.73-1.76) 8(15.7) 0.84(0.35-2.02) 39(22.3) 1.16(0.75-1.79) 31(21.4) 1.14(0.70-1.86) 
47-49 23(22.6) 1.40(0.79-2.47) 28(15.6) 1.00(0.62-1.63) 12(23.5) 1.32(0.60-2.89) 25(14.3) 0.87(0.53-1.43) 24(16.6) 1.07(0.63-1.81) 
50 -52 26(25.5) 1.00(referent) 43(23.9) 1.00(referent) 14(27.5) 1.00(referent) 45(25.7) 1.00(referent) 35(24.1) 1.00(referent) 
≥53 16(15.7) 1.01(0.54-1.91) 40(22.2) 1.49(0.96-2.31) 10(19.6) 1.21(0.52-2.79) 36(20.6) 1.35(0.86-2.10) 30(20.7) 1.41(0.86-2.33) 
Unknown 16(15.7) 1.26(0.63-2.51) 30(16.7) 1.18(0.72-.95) 7(13.7) 1.11(0.41-.06) 30(17.1) 1.26(0.76-2.09) 25(17.2) 1.17(0.68-2.03) 
P-trend  0.688  0.324  0.53  0.571  0.499 
Age at menopause, years           
≤46 24(22.4) 1.14(0.65-2.0) 49(25.4) 1.19(0.79-1.80) 9(17.0) 0.83(0.36-1.96) 47(25.4) 1.17(0.76-1.76) 40(25.5) 1.24(0.78-1.95) 
47-49 24(22.4) 1.37(0.78-2.38) 28(14.5) 0.92(0.57-1.47) 13(24.5) 1.37(0.64-2.95) 25(13.5) 0.82(0.50-1.34) 25(15.9) 1.01(0.60-1.69) 




≥53 16(15.0) 0.98(0.52-1.83) 40(20.7) 1.43(0.93-2.20) 10(18.9) 1.21(0.53-2.79) 36(19.5) 1.30(0.83-2.02) 30(19.1) 1.38(0.84-2.25) 
Unknown 16(15.0) 1.31(0.66-2.60) 30(15.5) 1.11(0.68-1.82) 7(13.2) 1.20(0.44-3.29) 30(16.2) 1.24(0.75-2.05) 25(15.9) 1.14(0.66-1.66) 
P-trend  0.635  0.479  0.532  0.681  0.415 
Use of MHT e           
No 60(46.9) 1.00(referent) 122(56.7) 1.00(referent) 28(41.2) 1.00(referent) 124(62.9) 1.00(referent) 102(55.7) 1.00(referent) 
Yes 53(41.4) 1.93(1.29-2.87) 85(39.5) 1.27(0.94-1.71) 31(45.6) 2.37(1.37-4.12) 73(37.1) 1.33(0.97-1.82) 79(43.2) 1.38(1.01-1.90) 
Unknown 15(11.7) 1.72(0.76-.87) 8(3.7)  9(13.2) 2.93(0.94-9.11) 13(6.2)  2(1.1)  
Duration MHT use, years e           
No 60(46.9) 1.00(referent) 122(56.7) 1.00(referent) 28(41.2) 1.00(referent) 124(59.1) 1.00(referent) 102(55.7) 1.00(referent) 
≤1.25 19(14.8) 2.31(1.35-3.94) 22(10.2) 1.11(0.70-1.77) 15(22.1) 3.77(1.95-7.31) 19(9.1) 1.10(0.67-1.80) 23(12.6) 1.39(0.88-2.22) 
>1.25-4 12(9.4) 1.47(0.77-2.80) 27(12.6) 1.60(1.03-2.48) 9(13.2) 2.28(1.03-5.04) 18(8.6) 1.16(0.69-1.94) 23(12.6) 1.54(0.96-2.47) 
>4 17(13.3) 2.32(1.29-4.17) 29(13.5) 1.11(0.72-1.72) 6(8.8) 1.79(0.70-4.60) 24(11.4) 1.48(0.92-2.38) 29(15.9) 1.28(0.82-2.02) 
Unknown duration 5(3.9)  7(3.3)  1(1.5)  12(5.7)  4(2.2)  
Unknown use of MHT 15(11.7) 1.56(0.67-3.61) 8(3.7)  9(13.2) 2.26(0.68-7.49) 13(6.2)  2(1.1)  
P-trend  0.002  0.242  0.023  0.100  0.199 
Type of MHT e, f           
Non-users of MHT 55(53.4) 1.00(referent) 111(58.4) 1.00(referent) 26(48.2) 1.00(referent) 114(64.0) 1.00(referent) 97(55.4) 1.00(referent) 
Oestrogen alone 7(6.8) 1.47(0.65-3.30) 19(10.0) 1.59(0.96-2.64) 5(9.3) 2.59(0.97-6.95) 13(7.3) 1.26(0.69-2.28) 20(11.4) 1.90(1.15-3.13) 
Oestrogen + Progestin 17(23.3) 1.57(0.84-2.94) 22(11.6) 0.92(0.56-1.50) 9(16.7) 1.59(0.67-3.77) 23(12.9) 1.09(0.65-1.80) 25(14.3) 1.10(0.68-1.78) 
Unknown type 24(23.3) 2.37(1.44-3.91) 38(20.0) 1.16(0.79-1.70) 14(25.9) 2.76(1.40-5.46) 28(15.7) 1.23(0.80-1.87) 33(18.9) 1.32(0.87-1.99) 
Oophorectomy g           
No 102(81.0)  171(77.4) 1.00(referent) 56(82.4)  170(78.7) 1.00(referent) 163(82.3) 1.00(referent) 
Unilateral 5(4.0)  16(7.2) 1.51(0.90-2.52) 3(4.4)  11(5.1) 1.06(0.57-1.95) 10(5.1) 0.96(0.51-1.83) 
Bilateral 5(4.0)  14(6.3) 1.36(0.78-2.36) 2(2.9)  11(5.1) 1.04(0.56-1.94) 13(6.6) 1.27(0.72-2.26) 
Unknown if unilateral 
or bilateral 
0(0)  1(0.5)  19(10.3)  24(11.1) 0.85(0.31-2.28) 1(0.5)  




Hysterectomy g           
No 99(78.6) 1.00(referent) 169(76.5) 1.00(referent) 55(80.5) 1.00(referent) 166(78.7) 1.00(referent) 152(76.8) 1.00(referent) 
Yes 20(15.9) 0.96(0.59 1.57) 38(17.2) 1.11(0.78-1.59) 11(16.2) 1.03(0.53-1.99) 37(17.1) 1.06(0.73-1.52) 35(17.7) 1.19(0.82-1.73) 
Unknown 7(5.6)  14(6.3)  2(2.9)  13(6.0)  11(5.6)  
Parity           
No 27(18.5) 1.00(referent) 29(12.6) 1.00(referent) 18(22.5) 1.00(referent) 29(12.5) 1.00(referent) 28(14.1) 1.00(referent) 
Yes 115(78.8) 0.59(0.39-0.90) 196(85.2) 0.91(0.62-1.35) 59(73.8) 0.44(0.26-0.75) 199(85.4) 0.96(0.65-1.43) 164(82.8) 0.80(0.54-1.20) 
Unknown 4(2.7)  5(2.2)  3(3.8)  5(2.2)  6(3.0)  
Number of full-term 
pregnancies h 
          
0 i 26(18.7) 1.42(0.81-2.51) 26(11.9) 0.79(0.48-1.29) 18(23.1) 1.70(0.83-3.46) 25(11.5) 0.80(0.48-1.33) 25(13.2) 0.90(0.53-1.52) 
1 23(16.5) 1.00(referent) 43(19.6) 1.00(referent) 14(18.0) 1.00(referent) 39(18.0) 1.00(referent) 34(18.0) 1.00(referent) 
2 43(30.9) 0.71(0.42-1.19) 89(40.6) 0.81(0.56-1.17) 24(30.8) 0.65(0.33-1.28) 77(35.5) 0.78(0.53-1.16) 70(37.0) 0.75(0.49-1.13) 
≥3 43(30.9) 0.83(0.49-1.41) 56(25.6) 0.59(0.39-0.90) 19(24.4) 0.63(0.30-1.29) 71(32.7) 0.81(0.53-1.21) 54(28.6) 0.68(0.44-1.07) 
Unknown 4(2.9)  5(2.3)  3(3.9)  5(2.3)  6(3.2)  
P-trend j  0.039  0.067  0.002  0.674  0.111 
Age at first full term 
pregnancy, years k 
          
≤20 15(13.0) 1.00(referent) 33(16.8) 1.00(referent) 12(20.3) 1.00(referent) 28(14.1) 1.00(referent) 23(14.0) 1.00(referent) 
21-23 30(26.1) 0.98(0.52-1.83) 57(29.1) 1.09(0.70-1.68) 13(22.0) 0.57(0.26-1.26) 49(24.6) 0.84(0.53-1.35) 54(32.9) 1.38(0.84-2.26) 
24-25 21(18.3) 0.83(0.42-1.64) 33(16.8) 0.88(0.53-1.44) 9(15.3) 0.51(0.21-1.25) 38(19.1) 0.81(0.49-1.35) 35(21.3) 1.13(0.65-1.94) 
26-30 38(33.0) 0.94(0.50-1.74) 55(28.1) 0.96(0.61-1.52) 22(37.3) 0.79(0.37-1.65) 60(30.2) 0.80(0.50-1.27) 39(23.8) 0.88(0.52-1.51) 
≥30 11(9.6) 0.85(0.38-1.88) 17(8.7) 0.96(0.53-1.76) 3(5.1) 0.33(0.09-1.22) 23(11.6) 0.95(0.54-1.68) 12(7.3) 0.91(0.44-1.87) 
Unknown   1(0.5)    1(0.5)  1(0.6)  
P-trend  0.702  0.661  0.402  0.713  0.196 
Breastfeeding j , k           




Yes 83(79.1) 0.82(0.49-1.36) 155(86.6) 0.97(0.62-1.51) 43(78.2) 0.66(0.33-1.32) 146(81.1) 0.83(0.56-1.24) 124(81.6) 0.78(0.50-1.20) 
Unknown 3(2.9)    1(1.8)  2(1.1)  2(1.3)  
Duration of breastfeeding, all 
pregnancies, months k, l 
          
>0-≤3 26(31.3) 1.00(referent) 53(34.2) 1.00(referent) 14(32.6) 1.00(referent) 46(31.5) 1.00(referent) 40(32.3) 1.00(referent) 
>3-12 39(47.0) 0.98(0.58-1.66) 66(42.6) 0.75(0.51-1.11) 16(37.2) 0.83(0.39-1.76) 68(46.6) 0.93(0.63-1.39) 55(44.4) 0.77(0.51-1.18) 
>12 18(21.7) 0.82(0.41-1.65) 33(21.3) 0.75(0.45-1.24) 13(30.2) 1.42(0.60-3.34) 31(21.2) 0.69(0.40-1.16) 27(21.8) 0.75(0.44-1.26) 
Unknown   3(1.9)    1(0.7)  2(1.6)  
P-trend  0.600  0.234  0.388  0.219  0.264 
Induced abortions m           
Never pregnant 17(15.9) 1.70(1.00-2.91) 19(9.8) 1.01(0.63-1.64) 13(21.7) 2.66(1.40-5.07) 16(9.0) 0.83(0.49-1.40) 18(10.0) 1.08(0.66-1.78) 
0 69(64.5) 1.00(referent) 137(70.6) 1.00(referent) 35(58.3) 1.00(referent) 134(74.4) 1.00(referent) 118(65.6) 1.00(referent) 
1 14(14.0) 1.90(1.05-3.42) 25(12.9) 1.04(0.67-1.62) 9(15.0) 1.67(0.77-3.61) 18(10.0) 1.22(0.73-2.04) 28(15.6) 1.28(0.83-1.96) 
≥2 5(3.5) 1.22(0.47-3.16) 11(5.7) 1.00(0.53-1.90) 2(3.3) 0.67(0.16-2.91) 10(5.6) 1.19(0.60-2.36) 14(7.80 1.36(0.76-2.43) 
Unknown 1(0.9)  2(1.0)  1(1.7)  2(1.1)  2(1.1)  
P-trend  0.657  0.947  0.119  0.261  0.733 
Spontaneous abortions n           
Never pregnant 22(17.3) 1.77(1.10-2.86) 19(9.4) 0.95(0.59-1.55) 17(23.6) 2.83(1.59-5.03) 17(8.6) 0.80(0.48-1.34) 18(10.0) 1.12(0.68-1.85) 
0 76(59.8) 1.00(referent) 135(66.5) 1.00(referent) 40(55.6) 1.00(referent) 128(65.0) 1.00(referent) 109(6 .7) 1.00(referent) 
1 21(16.5) 1.15(0.71-1.86) 33(16.3) 1.01(0.69-1.48) 10(13.9) 1.05(0.53-2.11) 35(17.8) 1.13(0.78-1.65) 36(20.0) 1.34(0.91-1.95) 
≥2 7(5.5) 0.96(0.44-2.09) 14(6.9) 1.25(0.72-2.17) 4(5.6) 1.16(0.41-3.24) 15(7.6) 1.26(0.72-2.15) 15(8.3) 1.61(0.93-2.77) 
Unknown 1(0.8)  2(1.0)  1(1.4)  2(1.0)  2(1.1)  
P-trend  0.225  0.710  0.048  0.164  0.095 
Fertility problems o           
No 82(73.2)  107(77.5)  45(75.0)  142(75.5) 90(69.2)   
Yes 7(6.3)  4(2.9)  2(3.3)  8(4.3) 9(6.9)   
Missing 23(20.5)  27(19.6)  13(21.7)  38(20.2) 31(23.9)   
OC: oral contraceptive // MHT: menopause hormone therapy 




a Available in all centres except San Sebastian, United Kingdom, Greece, Malmö, and Norway. 
bCox proportional hazards model stratified by centre and age at recruitment and adjusted by smoking status and intensity, fruits and vegetables intake. 
cCox proportional hazards model stratified by centre and age at recruitment and adjusted by smoking status and intensity, fruits and vegetables intake, OC use, and full-term pregnancies. 
d Women who had surgical menopause were excluded 
e In peri and postmenopausal women (natural or surgical). 
f Available in France, Italy, Spain, United Kingdom, The Netherlands, Germany, Denmark, and Norway. 
g Available in all centres except Malmö. 
h Available in all centres except Bilthoven. 
i Including nulliparous women and women without full-term pregnancies. 
j In parous women. 
k Available in all centres except Bilthoven and Umeå. 
l In parous women who has ever breastfed. 
m Available in all centres except Bilthoven, Umeå, Malmö, and Norway 
n Available in all centres except Bilthoven, Umeå, and Norway. 





Supplemental table 2: Multivariable-adjusted models for each individual reproductive factor, 
menstrual, menopausal factors, and exogenous hormone use in relation to UC by smoking status 
in EPIC Women. 
  Never  Former Current 
  Cases (%) 
n =195 HR (95%CI)
a Cases (%) 
n=133 HR (95%CI)
b Cases (%) 
n=197 HR (95%CI)
b 
Age at menarche, years             
<12 25 (12.8) 1.00 (referent) 13 (9.8) 1.00 (referent) 26 (13.2) 1.00 (referent) 
12 35 (18.0) 0.95 (0.57- 1.60) 31 (23.3) 1.73 (0.90- 3.34) 37 (18.8) 0.99 (0.60- 1.65) 
13 46 (23.6) 0.96 (0.59- 1.58) 26 (19.6) 1.01 (0.51- 1.99) 55 (27.9) 1.17 (0.72- 1.90) 
14 40 (20.5) 0.86 (0.52- 1.43) 32 (24.1) 1.24 (0.64- 2. 1) 35 (17.8) 0.76 (0.45- 1.29) 
>14 43 (22.1) 1.07 (0.64- 1.78) 29 (21.8) 1.26 (0.64- 2. 9) 39 (19.8) 0.97 (0.57- 1.63) 
Unknown 6 (3.1)   2 (1.5)   5 (2.5)   
P trend   0.847     0.874   0.506 
Cumulative duration of 
menstrual cycling, accounting 
for OC use, years c 
            
            
<23 26 (13.3) 1.00 (referent) 13 (9.8) 1.00 (referent) 33 (16.6) 1.00 (referent) 
23- <30 27 (13.9) 0.62 (0.35- 1.09) 30 (22.6) 1.86 (0.93- 3.71) 39 (19.8) 0.99 (0.60- 1.61) 
30- <35 37 (19.0) 0.55 (0.31- 0.96) 33 (17.3) 1.18 (0.56- 2.49) 47 (23.9) 1.05 (0.64- 1.74) 
≥35 64 (32.8) 0.75 (0.43- 1.28) 31 (23.3) 1.24 (0.58- 2.64) 45 (22.8) 1.15 (0.67- 1.97) 
Unknown 41 (21.0) 0.93 (0.53- 1.64) 36 (27.1) 1.81 (0.87 -3. 7) 33 (16.8) 0.73 (0.40- 1.33) 
P trend   0.863   0.857   0.725 
Use of OC             
No 123 (63.1) 1.00 (referent) 64 (48.1) 1.00 (referent) 90 (45.7) 1.00 (referent) 
Yes 68 (34.9) 0.84 (0.60- 1.18) 66 (49.6) 1.07 (0.72- 1.59) 102 (51.8) 0.93 (0.67- 1.28) 
Unknown 4 (2.1)   3 (2.3)   5 (2.5)   
Duration OC use, years              
No 123 (63.1) 1.00 (referent) 64 (48.1) 1.00 (referent) 90 (45.7) 1.00 (referent) 
>0- ≤1 11 (5.6) 0.71 (0.38- 1.33) 4 (3.0) 0.38 (0.14- 1.06) 19 (9.6) 0.85 (0.51- 1.44) 
>1- 5 15 (7.7) 0.69 (0.40- 1.21) 17 (12.8) 1.03 (0.58- 1.2) 30 (15.2) 1.08 (0.69- 1.68) 
>5- 10 20 (10.3) 1.20 (0.72- 1.99) 24 (18.1) 1.76 (1.05- 2.95) 23 (11.7) 0.93 (0.57- 1.53) 
>10 17 (8.7) 0.93 (0.53- 1.61) 9 (6.8) 0.59 (0.28- 1.24) 25 (12.7) 0.92 (0.57- 1.51) 
Unknown duration 5 (2.6)   12 (9.0)   5 (2.5)   
Missing use of OC 4 (2.1)   3 (2.3)   5 (2.5)   
P trend   0.359   0.72   0.615 
Menopausal status             
Premenopausal 18 (9.5) 1.00 (referent) 9 (6.8) 1.00 (referent) 22 (11.2) 1.00 (referent) 
Perimenopausal 19 (10.0) 1.05 (0.46- 2.39) 100 (75.2) 1.48 (0.46- 4.78) 140 (71.1) 3.57 (1.55- 8.24) 
Natural postmenopausal 150 (78.9) 0.78 (0.34- 1.78) 18 (13.5) 1.22 (0.39- 3.89) 27 (13.7) 2.31 (1.01- 5.30) 
Surgical postmenopuasal 8 (1.6) 1.07 (0.38- 3.05) 6 (4.5) 2.06 (0.51- 8.33) 8 (4.1) 
3.81 (1.33- 
10.94) 
Age at natural menopause, 
years d 
            
≤46 25 (16.7) 1.15 (0.67- 1.93) 19 (19.0) 1.01 (0.55- 1.85) 41 (29.3) 1.23 (0.76- 1.97) 




50 - 52 36 (24.0) 1.00 (referent) 26 (26.0) 1.00 (referent) 35 (25.0) 1.00 (referent) 
≥53 35 (23.3) 1.25 (0.75- 2.10) 22 (22.0) 1.27 (0.71- 2.29) 19 (13.6) 1.12 (0.63- 2.00) 
Unknown 28 (18.7) 1.84 (1.07- 3.16) 17 (17.0) 1.07 (0.55- 2.10) 19 (13.6) 1.05 (0.57- 1.93) 
P trend   0.532   0.592   0.562 
Age at any menopause, years             
≤46 29 (18.4) 1.11 (0.68- 1.81) 24 (22.6) 1.13 (0.64- 2.00) 47 (31.8) 1.28 (0.81- 2.02) 
47- 49 26 (16.5) 1.13 (0.68- 1.88) 16 (15.1) 1.05 (0.56- 1.97) 28 (18.9) 0.96 (0.57- 1.60) 
50 - 52 39 (24.7) 1.00 (referent) 27 (25.5) 1.00 (referent) 35 (23.7) 1.00 (referent) 
≥53 36 (22.8) 1.44 (0.91- 2.29) 22 (20.8) 1.25 (0.70- 2.22) 19 (12.8) 1.13 (0.64- 2.02) 
Unknown 28 (17.7) 1.75 (1.02- 2.97) 17 (16.0) 1.05 (0.54- 2.03) 19 (12.8) 1.07 (0.59- 1.96) 
P trend   0.464   0.954   0.424 
Use of MHT e             
No 105 (59.3) 1.00 (referent) 63 (47.4) 1.00 (referent) 77 (39.1) 1.00 (referent) 
Yes 52 (29.4) 1.02 (0.71- 1.47) 45 (33.8) 1.21 (0.80- 1.84) 73 (37.1) 1.58 (1.12- 2.23) 
Unknown 20 (11.3) 1.14 (0.58- 2.25) 25 (18.8) 0.87 (0.41- 1.85) 47 (23.9) 2.55 (1.34- 4.86) 
Duration MHT use, years e             
No 105 (59.3) 1.00 (referent) 63 (47.4) 1.00 (referent) 77 (39.1) 1.00 (referent) 
>0- ≤1.25 18 (10.2) 1.16 (0.69- 1.95) 10 (7.5) 1.07 (0.54- 2.11) 22 (11.2) 1.73 (1.06- 2.82) 
>1.25-4 12 (6.8) 0.87 (0.47- 1.62) 14 (10.5) 1.50 (0.82- 2.76) 21 (10.7) 1.87 (1.12- 3.10) 
>4 19 (10.7) 1.24 (0.73- 2.11) 14 (10.5) 1.23 (0.66- 2.30) 22 (11.2) 1.26 (0.75- 2.11) 
Unknown duration 3 (1.7)   7 (5.3)   8 (4.1)   
Unknown use of MHT 20 (11.3)   25 (18.8)       
        P trend   0.567   0.412   0.421 
Type of MHT  e, f             
Non-users of MHT 88 (63.8) 1.00 (referent) 52 (57.1) 1.00 (referent) 73 (52.5) 1.00 (referent) 
Oestrogen alone 7 (5.1) 0.87 (0.40- 1.92) 8 (8.8) 1.41 (0.65- 3.07) 17 (12.2) 2.08 (1.19- 3.62) 
Oestrogen + Progestin 22 (15.9) 1.22 (0.72- 2.08) 14 (15.4) 1.21 (0.63- 2. 2) 13 (9.4) 0.79 (0.42- 1.48) 
Unknown type of MHT 21 (15.2) 1.10 (0.67- 1.80) 17 (18.7) 1.49 (0.84- 2.66) 36 (25.9) 1.68 (1.10- 2.56) 
Oophorectomy g             
No 141 (82.0) 1.00 (referent) 76 (70.4) 1.00 (referent) 125 (74.4) 1.00 (referent) 
Unilateral 9 (5.2) 1.21 (0.61- 2.40) 6 (5.6) 1.03 (0.44- 2.39) 13 (7.7) 1.51 (0.84- 2.70) 
Bilateral 8 (4.7) 0.91 (0.44- 1.87) 6 (5.6) 1.21 (0.52- 2.83) 9 (5.4) 1.25 (0.62- 2.52) 
Unknown if unilateral or       
bilateral 
    1 (0.93)       
Unknown 14 (8.1) 0.07 (0.00- 1.29) 19 (17.6) 1.25 (0.45- 3.48) 21 (12.5) 2.00 (0.79- 5.03) 
Hysterectomy g             
No 139 (80.8) 1.00 (referent) 76 (70.4) 1.00 (referent) 127 (75.6) 1.00 (referent) 
Yes 23 (13.4) 0.83 (0.53- 1.30) 20 (18.5) 1.11 (0.67- 1.84) 32 (19.1) 1.38 (0.92- 2.08) 
Unknown 10 (5.8) 0.61 (0.19- 1.95) 12 (11.1) 1.22 (0.42- 3.53) 9 (5.4) 0.89 (0.27- 2.94) 
Parity             
No  19 (9.7) 1.00 (referent) 26 (19.6) 1.00 (referent) 27 (13.7) 1.00 (referent) 
Yes 170 (87.2) 1.23 (0.76- 1.99) 103 (77.4) 0.61(0.39- 0. 5) 164 (83.3) 1.35(0.51- 3.61) 
Unknown 6 (3.1)   4 (3.0)   6 (3.1)   
Number of full-term 
pregnancies h 
            




1 32 (16.6) 1.00 (referent) 26 (20.5) 1.00 (referent) 40 (21.4) 1.00 (referent) 
2 83 (43.0) 0.96 (0.63- 1.45) 36 (28.4) 0.57 (.34- 0.96) 72 (38.5) 0.78 (0.52- 1.16) 
3 39 (20.2) 0.85 (0.52- 1.37) 25 (19.7) 0.74 (0.42- 1.31) 24 (12.8) 0.47 (0.27- 0.79) 
4 9 (4.7) 0.56 (0.26- 1.20) 11 (8.7) 0.93 (0.45- 1.93) 15 (8.0) 1.00 (0.54- 1.85) 
≥5 5 (2.6) 0.48 (0.18- 1.28) 0 (0)   6 (3.2) 0.77 (0.32- 1.86) 
Unknown parity 6 (3.1)   4 (3.2)   6 (3.2)   
P-trend j    0.064   0.208   0.127 
Age at first full-term 
pregnancy, years j
            
≤20  19 (11.2) 1.00 (referent) 13 (12.6) 1.00 (referent) 36 (22.0) 1.00 (referent) 
21- 23  40 (23.5) 0.95 (0.55- 1.65) 32 (31.1) 1.31 (0.68- 2.51) 45 (27.4) 0.91 (0.58- 1.44) 
24- 25  34 (20.0) 0.90 (0.51- 1.61) 15 (14.6) 0.77 (0.36- 1. 6) 24 (14.6) 0.79 (0.46- 1.35) 
26- 30  57 (33.5) 0.93 (0.54- 1.58) 35 (34.0) 1.18 (0.61- 2.29) 47 (28.7) 1.01 (0.64- 1.60) 
≥30  20 (11.8) 0.98 (0.51- 1.86) 7 (6.8) 0.73 (0.28- 1.85) 12 (7.3) 0.78 (0.40- 1.54) 
Unknown      1 (1.0)       
 P-trend   0.906   0.552   0.745 
Breastfeeding j, k             
 No 24 (14.9) 1.00 (referent) 9 (9.9) 1.00 (referent) 24 (15.7) 1.00 (referent) 
 Yes 133 (82.6) 0.78 (0.50- 1.22) 79 (86.8) 1.17 (0.58- 2.38) 127 (83.0) 0.70 (0.45- 1.11) 
Unknown 4 (2.5)   3 (3.3)   2 (1.3)   
Duration of breastfeeding, all 
pregnancies, months k, l 
            
>0-≤3  49 (36.8) 1.00 (referent) 28 (35.4) 1.00 (referent) 38 (29.9) 1.00 (referent) 
>3- 12 49 (36.8) 0.51 (0.34- 0.78) 32 (40.5) 0.60 (0.36- 1.02) 61 (48.0) 1.00 (0.65- 1.53) 
>12  34 (25.6) 0.47 (0.29- 0.76) 19 (24.1) 0.78 (0.42- 1.44) 25 (19.7) 1.02 (0.60- 1.76) 
Unknown 1 (0.8)           
 P-trend   0.015   0.341   0.937 
Induced abortions m             
Never pregnant 14 (9.0) 0.90 (0.51- 1.59) 17 (19.8) 1.77 (1.01- 3.09) 16 (11.3) 1.05 (0.61- 1.81) 
0 114 (73.1) 1.00 (referent) 56 (65.1) 1.00 (referent) 98 (68.0) 1.00 (referent) 
1 15 (9.6) 1.29 (0.73- 2.26) 9 (10.5) 1.23 (0.58- 2.86) 21 (14.8) 1.04 (0.63- 1.69) 
≥2 12 (7.7) 2.52 (1.33- 4.78) 2 (2.3) 0.65 (0.15- 2.74) 5 (3.5) 0.43 (0.17- 1.08) 
Unknown 1 (0.6)   2 (2.3)   2 (1.4)   
P-trend   0.012   0.091   0.175 
Spontaneous abortions n             
Never pregnant 16 (8.9) 0.84 (0.49- 1.42) 20 (18.0) 1.65 (0.99- 2.77) 19 (11.1) 1.16 (0.68- 1.84) 
0 120 (67.0) 1.00 (referent) 67 (60.4) 1.00 (referent) 108 (63.2) 1.00 (referent) 
1 35 (19.6) 1.26 (0.86- 1.84) 15 (13.5) 0.91 (0.52- 1.60) 27 (15.8) 1.08 (0.71- 1.67) 
≥2 7 (3.9) 0.69 (0.32- 1.49) 6 (5.4) 1.06 (0.46- 2.46) 14 (8.2) 1.52 (0.86- 2.68) 
Unknown 1 (0.6)   3 (2.7)   3 (1.8)   
P-trend   0.679   0.185   0.375 
Infertility problems o             
No 122 (89.7) 1.00 (referent) 57 (79.2) 1.00 (referent) 75 (77.3) 1.00 (referent) 
Yes 4 (2.9) 0.93 (0.34- 2.55) 7 (9.7) 3.12(1.38- 7.04) 5 (5.2) 1.32(0.50- 3.49) 
Unknown 10 (7.4)   8 (11.1) 2.34(0.95- 5.74) 17 (17.5) 0.44(0.12- 1.55) 
UC: urothelial carcinoma // OC: oral contraceptive // MHT: menopause hormone therapy 
Estimation of “Unknown” category is provided when more than 10% of the cases are classified as “Unknown”. 




a Cox proportional hazards model stratified by centre and age at recruitment and adjusted by fruits and vegetables 
intake. 
b Cox proportional hazards model stratified by centre and age at recruitment and adjusted by smoking intensity 
(number of cigarettes per day in current-smokers and time since quitting smoking in former-smokers), fruits and 
vegetables intake. 
c Cox proportional hazards model stratified by centre and age at recruitment and adjusted by smoking status and 
intensity, fruits and vegetables intake, OC use, and full-term pregnancies 
d Women who had surgical menopause were excluded 
e In peri- and postmenopausal (natural or surgical). 
f Available in France, Italy, Spain, United Kingdom, The Netherlands, Germany, Denmark, and Norway. 
g Available in all centres except Malmö. 
h Available in all centres except Bilthoven. 
i Including nulliparous women and women without full-term pregnancies. 
j In parous women. 
k Available in all centres except Bilthoven and Umeå. 
l In parous women who has ever breastfed. 
m Available in all centres except Bilthoven, Malmö, Umeå, and Norway. 
n Available in all centres except Bilthoven, Umeå, andNorway. 








Supplemental table 3: Mutually adjusted models for menopause status, MHT, and parity, and UC by smoking status 
 Never Former Current 
 
Cases (%) 
n =195 HR (95%CI)
a Cases (%) n =133 HR (95%CI)
b Cases (%) n =197 HR (95%CI)
b 
   Menopausal status & use of MHT       
Premenopausal  18 (9.23) 1.23 (0.52- 2.43) 9 (6.8) 0.83 (0.27- 2.54) 22 (11.2) 0.50 (0.22- 1.11) 
Peri-/Postmenopausal & non-users of MHT 105 (53.9) 1.00 (referent) 63 (47.4) 1.00 (referent) 77 (39.1) 1.00 (referent) 
Peri-/Postmenopausal & users of MHT 52 (26.7) 1.02 (0.71- 1.47) 45 (33.8) 1.20 (0.79- 1.83) 73 (37.1) 1.56 (1.10- 2.21) 
Peri-/Postmenopausal & unknown MHT-use 20 (10.26) 1.12 (0.53- 2.39) 16 (12.0) 0.89 (0.40- 2.00) 25 (12.7) 2.31 (1.16- 4.62) 
   Number of full-term pregnancies c       
0 d 19 (9.7) 0.72 (0.40- 1.29) 26 (19.6) 1.17 (0.67- 2.06) 27 (13.7) 0.83 (0.49- 1.39) 
1 32 (16.4) 1.00 (referent) 26 (19.6) 1.00 (referent) 40 (20.3) 1.00 (referent) 
2 83 (42.6) 0.95 (0.63- 1.45) 36 (27.1) 0.57 (0.34- 0.96) 72 (36.6) 0.78 (0.49- 1.39) 
3 39 (20.0) 0.85 (0.52- 1.37) 25 (18.8) 0.74 (0.42- 1.30) 24 (12.2) 0.48 (0.28- 0.81) 
4 9 (4.6) 0.57 (0.27- 1.21) 11 (8.3) 0.94 (0.45- 1.95) 15 (7.6) 1.01 (0.54- 1.88) 
≥5 5 (2.6) 0.49 (0.18- 1.29)   
6 (3.1) 0.80 (0.33- 1.95) 











UC: urothelial carcinoma // MHT: menopause hormone therapy 
Estimation of “Unknown” category is provided when more than 10% of the cases are classified as “Unknown”. 
All P value for the interaction were >0.10 
a Cox proportional hazards model stratified by centre and age at recruitment and adjusted by fruits and vegetables intake. 
b Cox proportional hazards model stratified by centr and age at recruitment and adjusted by smoking intensity (number of cigarettes per day in current-smokers and time since quitting  
smoking in former-smokers), fruits and vegetables intake. 
c Available in all centres except Bilthoven. 
d Including nulliparous women and women without full-term pregnancies. 
e In parous women. 
 
